Old College Capital, a limited partnership, is the newly created arm of the University of Edinburgh, which will invest in some of its leading spin-out and start-up companies.
Biovex, a cancer vaccine developer spun out of University College London (UCL) a decade ago, was acquired in January by US biotechnology giant Amgen for $1 billion.